SearchBox:

Search Term: " Phillip "

  Messages 1-2 from 2 matching the search criteria.
Allibiotic CF Fact Sheet Darrell Miller 12/7/05
REFERENCES Darrell Miller 6/22/05




Allibiotic CF Fact Sheet
TopPreviousNext

Date: December 07, 2005 01:37 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: Allibiotic CF Fact Sheet

Allibiotic CF Fact Sheet

Neil E. Levin, CCN, DANLA 03/09/05

LIKELY USERS: People seeking support of the immune system and intestinal flora

KEY INGREDIENTS: Allicin (“AlliSure” patented, stabilized allicin from fresh garlic); Olive Leaf Extract (Olea Europaea with 18% minimum Oleuropein content); Elderberry extract, from fruit/berry, 60:1 concentrate (equivalent to 2,500 mg. of fresh berries of Sambucus nigra); Oil of Oregano (wild oregano from Origanum vulgare) ImmunEnhancer AG (trademarked Arabinogalactan from Larch Tree, Larix occidentalis)

MAIN PRODUCT FEATURES: AlliSure is the clinically tested, patented and stable form of allicin. Not allicin potential, but actual allicin. Allicin represents the immune supporting nutrients of raw garlic, and is chemically similar to penicillin, though with different physical properties. AlliSure shares garlic’s abilities to help maintain healthy cholesterol and blood pressure levels, and also has been shown to raise levels of a key T cell to enhance immune system function. Like raw garlic, AlliSure has antimicrobial properties linked to its ability to react with sulfur-containing metabolic enzymes. Allicin is also shown in studies to play a role in controlling blood sugar and abnormal cell growth.

Black Elderberries have strong antioxidant properties, containing flavonoids like anthocyanidins. They have been studied in relation to inhibition of viral replication and of minor inflammations.

Olive Leaf has been used as an antioxidant, cholesterol and blood viscosity regulator, and vasodilator. But its most important use has been as a way to help the body deal with undesirable organisms in the vital respiratory and intestinal areas.

Oil of Oregano (wild oregano, wild marjoram) contains carvacrol and thymol, which are responsible for much of its antimicrobial activities. It also has some anti-inflammatory effects.

Arabinogalactan from Larch tree bark (ImmunEnhancer AG) can help speed the immune system’s response to undesirable organisms and is often compared to Echinacea. It has also been shown to promote the growth of beneficial intestinal bacteria.

ADDITIONAL PRODUCT INFORMATION: Patented and trademarked ingredients enhance quality controls and have clinical research. Rosemary Oil provides antioxidant protection for the capsule contents. Enteric coating protects the capsule from stomach acid to deliver its contents past the stomach. This helps to assure full potency and reduces the possibility of the oils repeating.

SERVING SIZE & HOW TO TAKE IT: One softgel twice daily, preferably with meals. Try one before using the full dose.

COMPLEMENTARY PRODUCTS: Probiotics, Antioxidants, D-Flame

CAUTIONS: Pregnant & lactating women, children and people using prescription drugs should consult their physician before taking any dietary supplement. Discontinue use if any uncomfortable side effects occur. This information is based on my own knowledge and references, and should not be used as diagnosis, prescription or as a specific product claim.

Disclaimer: These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

REFERENCES:

ALLICIN:

Josling P. Preventing the common cold with a garlic supplement: a double-blind, placebo-controlled survey. Adv Ther. 2001 Jul-Aug;18(4):189-93. (AlliSure was used in this study.)

Abramovitz D, Gavri S, Harats D, Levkovitz H, Mirelman D, Miron T, Eilat-Adar S, Rabinkov A, Wilchek M, Eldar M, Vered Z. Allicin-induced decrease in formation of fatty streaks (atherosclerosis) in mice fed a cholesterol-rich diet. Coron Artery Dis. 1999 Oct;10(7):515-9. PMID: 10562920

Ankri S, Miron T, Rabinkov A, Wilchek M, Mirelman D. Allicin from garlic strongly inhibits cysteine proteinases and cytopathic effects of Entamoeba histolytica. Antimicrob Agents Chemother. 1997 Oct;41(10):2286-8. PMID: 9333064

Cellini L, Di Campli E, Masulli M, Di Bartolomeo S, Allocati N. Inhibition of Helicobacter pylori by garlic extract (Allium sativum). FEMS Immunol Med Microbiol. 1996 Apr;13(4):273-7. PMID: 8739190

Chowdhury AK, Ahsan M, Islam SN, Ahmed ZU. Efficacy of aqueous extract of garlic & allicin in experimental shigellosis in rabbits. Indian J Med Res. 1991 Jan;93:33-6.

Eilat S, Oestraicher Y, Rabinkov A, Ohad D, Mirelman D, Battler A, Eldar M, Vered Z. Alteration of lipid profile in hyperlipidemic rabbits by allicin, an active constituent of garlic. Coron Artery Dis. 1995 Dec;6(12):985-90. PMID: 8723021

Elkayam A, Mirelman D, Peleg E, Wilchek M, Miron T, Rabinkov A, Oron-Herman M, Rosenthal T. The effects of allicin on weight in fructose-induced hyperinsulinemic, hyperlipidemic, hypertensive rats. Am J Hypertens. 2003 Dec;16(12):1053-6. PMID: 14643581

Feldberg RS, Chang SC, Kotik AN, Nadler M, Neuwirth Z, Sundstrom DC, Thompson NH. In vitro mechanism of inhibition of bacterial cell growth by allicin. Antimicrob Agents Chemother. 1988 Dec;32(12):1763-8.

Focke M, Feld A, Lichtenthaler K. Allicin, a naturally occurring antibiotic from garlic, specifically inhibits acetyl-CoA synthetase. FEBS Lett. 1990 Feb 12;261(1):106-8.

Hirsch K, Danilenko M, Giat J, Miron T, Rabinkov A, Wilchek M, Mirelman D, Levy J, Sharoni Y. Effect of purified allicin, the major ingredient of freshly crushed garlic, on cancer cell proliferation. Nutr Cancer. 2000;38(2):245-54. PMID: 11525603

Patya M, Zahalka MA, Vanichkin A, Rabinkov A, Miron T, Mirelman D, Wilchek M, Lander HM, Novogrodsky A. Allicin stimulates lymphocytes and elicits an antitumor effect: a possible role of p21ras. Int Immunol. 2004 Feb;16(2):275-81. PMID: 14734613

Rabinkov A, Miron T, Mirelman D, Wilchek M, Glozman S, Yavin E, Weiner L. S-Allylmercaptoglutathione: the reaction product of allicin with glutathione possesses SH-modifying and antioxidant properties. Biochim Biophys Acta. 2000 Dec 11;1499(1-2):144-153. PMID: 11118647

Rabinkov A, Miron T, Konstantinovski L, Wilchek M, Mirelman D, Weiner L. The mode of action of allicin: trapping of radicals and interaction with thiol containing proteins. Biochim Biophys Acta. 1998 Feb 2;1379(2):233-44. PMID: 9528659

Sela U, Ganor S, Hecht I, Brill A, Miron T, Rabinkov A, Wilchek M, Mirelman D, Lider O, Hershkoviz R. Allicin inhibits SDF-1alpha-induced T cell interactions with fibronectin and endothelial cells by down-regulating cytoskeleton rearrangement, Pyk-2 phosphorylation and VLA-4 expression. Immunology. 2004 Apr;111(4):391-9. PMID: 15056375

Shadkchan Y, Shemesh E, Mirelman D, Miron T, Rabinkov A, Wilchek M, Osherov N. Efficacy of allicin, the reactive molecule of garlic, in inhibiting Aspergillus spp. in vitro, and in a murine model of disseminated aspergillosis. J Antimicrob Chemother. 2004 May;53(5):832-6. Epub 2004 Mar 24. PMID: 15044429

Tsai Y, Cole LL, Davis LE, Lockwood SJ, Simmons V, Wild GC. Antiviral properties of garlic: in vitro effects on influenza B, herpes simplex and coxsackie viruses. Planta Med. 1985 Oct;(5):460-1. PMID: 3001801

Uchida Y, Takahashi T, Sato N. [The characteristics of the antibacterial activity of garlic (author's transl)] Jpn J Antibiot. 1975 Aug;28(4):638-42. PMID: 1099271

Yasuo Yamada and Keizô Azuma. Evaluation of the In Vitro Antifungal Activity of Allicin. Antimicrob Agents Chemother. 1977 April; 11(4): 743–749.

ELDERBERRY:

Duke JA. CRC Handbook of Medicinal Herbs. Boca Raton, FL: CRC Press, 1985, 423.

Gruenwald J, Brendler T, Jaenicke C, et al. (eds). PDR for Herbal Medicines. Montvale, NJ: Medical Economics, 1998, 1116–7.

Mascolo N, Autore G, Capasso G, et al. Biological screening of Italian medicinal plants for anti-inflammatory activity. Phytother Res 1987;1:28–31.

Murkovic M, Abuja PM, Bergmann AR, et al. Effects of elderberry juice on fasting and postprandial serum lipids and low-density lipoprotein oxidation in healthy volunteers: a randomized, double-blind, placebo-controlled study. Eur J Clin Nutr. Feb2004;58(2):244-9.

Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. London: The Pharmaceutical Press, 1996, 104–5.

Yesilada E. Inhibitory Effects of Turkish Folk Remedies on Inflammatory Cytokines: Interleukin-1Alpha, Interleukin-1Beta and Tumor Necrosis Factor Alpha. J Ethnopharmacol. Sept1997;58(1):59-73. Youdim KA, Martin A, Joseph JA. Incorporation of the elderberry anthocyanins by endothelial cells increases protection against oxidative stress. Free Radical Biol Med 2000;29:51–60.

Zakay-Rones Z, Varsano N, Zlotnik M, et al. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B Panama. J Alt Compl Med 1995;1:361–9.

OLIVE LEAF EXTRACT:

American Herbal Products Association. Use of Marker Compounds in Manufacturing and Labeling Botanically Derived Dietary Supplements. Silver Spring, MD: American Herbal Products Association; 2001.

Bennani-Kabchi N, et al. Effects of Olea europea var. oleaster leaves in hypercholesterolemic insulin-resistant sand rats. Therapie. Nov1999;54(6):717-23.

Bisignano G, et al. On the in-vitro antimicrobial activity of oleuropein and hydroxytyrosol. J Pharm Pharmacol. Aug1999;51(8):971-4. Gonzalez M, et al. Hypoglycemic activity of olive leaf. Planta Medica. 1992;58:513-515. Visoli F, et al. Oleuropein protects low density lipoprotein from oxidation. Life Sciences. 1994;55:1965-71. PDR for Herbal Medicines, 2nd edition. Montvale, NJ: Medical Economics Company; 2000:557.

Petroni A, et al. Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil.Thromb Res. Apr1995;78(2):151-60. Pieroni A, et al. In vitro anti-complementary activity of flavonoids from olive (Olea europaea L.) leaves. Pharmazie. Oct1996;51(10):765-8. Zarzuelo A, et al. Vasodilator effect of olive leaf. Planta Med. Oct1991;57(5):417-9. OREGANO OIL (OIL OF OREGANO, WILD OREGANO, WILD MARJORAM):

Dorman HJ, et al. Antimicrobial agents from plants: antibacterial activity of plant volatile oils. J Appl Microbiol. Feb2000;88(2):308-16. Force M, et al. Inhibition of enteric parasites by emulsified oil of oregano in vivo. Phytother Res. May2000;14(3):213-4.

Hammer KA, Carson CF, Riley TV. Antimicrobial activity of essential oils and other plant extracts. J Appl Microbiol 1999;86:985–90.

Kelm MA, Nair MG, Strasburg GM. Antioxidant and Cyclooxygenase Inhibitory Phenolic Compounds from Ocimum sanctum Linn. Phytomedicine. Mar2000;7(1):7-13. Lamaison JL, et al. Medicinal Lamiaceae with antioxidant properties, a potential source of rosmarinic acid. Pharm Acta Helv. 1991;66(7):185-8.

Ponce MM, Navarro AI, Martinez GMN, et al. In vitro effect against Giardia of 14 plant extracts. Rev Invest Clin 1994;46:343–7 [in Spanish].

Stiles JC, Sparks W, Ronzio RA. The inhibition of Candida albicans by oregano. J Applied Nutr 1995;47:96–102.

Tantaoui EA, Beraoud L. Inhibition of growth and aflatoxin production in Aspergillus parasiticus by essential oils of selected plant materials. J Environ Pathol Toxicol Oncol 1994;13:67–72. ImmunEnhancer AG (Larch tree Arabinogalactan)

Corado J, et al. Impairment of Natural Killer (NK) Cytotoxic Activity in Hepatitis C Virus (HCV) Infection. Exp Immunol. 1997;109:451-457. Currier NL, Lejtenyi D, Miller SC. Effect over time of in-vivo administration of the polysaccharide arabinogalactan on immune and hemopoietic cell lineages in murine spleen and bone marrow. Phytomedicine. 2003 Mar;10(2-3):145-53. PMID: 12725568

Egert D, et al. Studies on Antigen Specificity of Immunoreactive Arabinogalactan Proteins Extracted from Baptisia tinctoria and Echinacea purpurea. Planta Med. 1992;58:163-165. Gonda R, et al. Arabinogalactan Core Structure and Immunological Activities of Ukonan C, An Acidic Polysaccharide from the Rhizome of Curcuma longa. Biol Pharm Bull. 1993;16:235-238. Hagmar B, et al. Arabinogalactan Blockade of Experimental Metastases to Liver by Murine Hepatoma. Invasion Metastasis. 1991;11:348-355. Kelly GS. Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide. Altern Med Rev. 1999 Apr;4(2):96-103. Review. PMID: 10231609

Kim LS, Waters RF, Burkholder PM. Immunological activity of larch arabinogalactan and Echinacea: a preliminary, randomized, double-blind, placebo-controlled trial. Altern Med Rev. 2002 Apr;7(2):138-49. PMID: 11991793

Levine PH, et al. Dysfunction of Natural Killer Activity in a Family With Chronic Fatigue Syndrome. Clin Immunol Immunopathol. 1998;88:96-104. Robinson RR, Feirtag J, Slavin JL. Effects of dietary arabinogalactan on gastrointestinal and blood parameters in healthy human subjects. J Am Coll Nutr. 2001 Aug;20(4):279-85. PMID: 11506055

Rolfe RD. The Role of Probiotic Cultures in the Control of Gastrointestinal Health. J Nutr. Feb2000;130(2S Suppl):396S-402S.

Salyers AA, Vercellotti JR, West SE, Wilkins TD. Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol. 1977 Feb;33(2):319-22. PMID: 848954

Uchida A. Therapy of Chronic Fatigue Syndrome. Nippon Rinsho. 1992;50:2679-2683.



--
Vitanet ®

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=987)


REFERENCES
TopPreviousNext

Date: June 22, 2005 09:57 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: REFERENCES

REFERENCES


1. Interview with Dr. Michael Pariza, July 3, 1997.
2. “Effects of Temperature and Time on Mutagen Formation in Pan-Fried Hamburger,” by M. Pariza, Samy Ashoor, Fun Chu and Daryl Lund, March 10, 1979, Cancer Letters, 7 (1979) 63-69.
3. “Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid,” Y.L Ha, N.K. Grimm and M.W. Pariza, August 25, 1987. IRL Press limited, Oxford, England.
4. Interview with Dr. Mark Cook, July 3, 1997.
5. “Conjugated Linoleic Acid in Cancer Prevention Research: A Report of Current Status and Issues,” A special report prepared for the National Live Stock and Meat Board, Ip, Clement, Ph.D., May 1994. See also “Conjugated linoleic acid, a newly recognised nutrient” in the June 17, 1997, issue of Chemistry and Industry by M. Pariza, pp. 464-466.
6. Op.Cit. Pariza, Chemistry and Industry.
7. Op. Cit. Ip, National Live Stock and Meat Board. See also, “Conjugated Linoleic Acid (9,11 and 10,12-Octadecadienoic Acid) is Produced in Conventional by Not Germ-Free Rats Fed Linleic Acid,” Sou F. Chin, Et. Al, Dec. 16, 1993, Journal of Nutrition 124: 694-701 1994.
8. Ibid.
9. Interview with Cook. 10. Op. Cit. Ip, National Live Stock and Meat Board.
11. Ibid.
12. Op. Cit., interview with Pariza., and “Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid,” Y.L. Ha, N.K. Grimm and M.W. Pariza, Aug. 25, 1987, IRL Press Limited, Oxford England.
13. “Conjugated linoleic acid: An anticarcinogenic fatty acid present in mile fat,” by Peter Parodi, Australian Journal of DairyTechnology. Nov. 1994, 49 p. 93-94.
14. The Washington Post “Now We’re a Nation of Lite Heavyweights,” Sept. 1, 1994, Sec. B. P. 10.
15. “A beef-derived mutagenesis modulator inhibits initiation of mouse epidermal tumors by 7, 12 dimethylbens[a]anthracene,” by M. Pariza and W. Hargraves, Jan. 2, 1985, Carcinogenesis, vol 6., no. 4 pp. 591-593, 1985, IRL Press, Limited, Oxford, England.
16. Op. Cit. Pariza, Chemistry and Industry.
17. “Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid,” Y.L. Ha, N.K. Grimm and M.W. Pariza, Aug. 25, 1987, IRL Press Limited, Oxford England.
18. “Mammary Cancer Prevention by Conjugated Dienoic Derivative of Linoleic Acid,” Clement Ip, Sou Fe Chin, Joseph Scimeca and Michael Pariza, Cancer Research, 51, 6118-6124, Nov. 15, 1991.
19. “Refiguring the Odds: What’s a woman’s real chance of suffering breast cancer?” Facklemann, K.A., Science News 144 (1993) 76-77.
20. “Inhibition of benzo(a)pyrene-induced mouse forestomach neoplasia by conjugated dienoic derivatives of linoleic acid.” Ha, Y.L, Storkson, J., Pariza, M.W. Cancer Research 50: 1097-1101; 1990.
21. “Protection of Conjugated linoleic acid against 2-amino-3-methylimidazo [4,5-f]quinoline-induced colon carcinogenesis in the f344 rat: a study of inhibitory mechanisims,” Liew, C.; Schut, H.A.J., chin, S.F., Pariza, M.W., and Dashwood, R.H. (1995), Carcinogenesis 16, 3037-3044.
22. Op. Cit., Ip, Cancer Research, 1991.
23. “Potential of Food Modification in Cancer Prevention,” Ip, C.; Lisk, Donald J. and J. Scimeca, Cancer Research, 54, 1957-1959, April 1, 1994.
24. “Conjugated Linoleic Acid (CLA), A Newly Re c o g n i ze d Anitcarcinogenic Nutrient,” unpublished paper by Michael Pariza.
25. “Effects of conjugated dienoic linoleic acid on lipid metabolism in mouse liver,” Belury, M.A. and Vanden Heuvel, J.P. (1996), Proc. Am. Assoc. Cancer Res. 37: 1918.
26. “Protection Against Cancer and Heart Disease by Dietary Fatty Acid, Conjugated Linoleic Acid: Potential Mechanisms of Action,” Belury, M.A.; Vanden Heuvel, J.P; Submitted to Nutrition and Disease Update Journal, Sept. 28, 1996.
27. Interveiw with Pariza.
28. Op. Cit., Pariza, Cancer Research, 1990.
29. “Fatty Acids that Inhibit Cancer,” unpublished paper by M. Pariza.
30. Op. Cit. Liew.
31. “Reinvestigation of the antioxidant properties of conjugated linoleic acid,” van den Berg J.J.; Cook, N.E.; Tribble D.L.; Lipids, 73, 1995, Jul 30 (7), 595-598.
32. “Furan Fatty acids detrmined as oxidation products of conjugated octadecadienoic acid,” Yurawecz, M.P., Hood, J.K., Mossoba, MM., Roach, J.A.G., and Ku, Y. Lipids 30, 595-598.
33. Interview with Pariza.
34. “Vital Statistics of the United States” from the Centers for Disease Control for 1989.
35. “Conjugated linoleic acid and atherosclerosis in rabbits.” Lee, K.N., Kritchevsky, D. And Pariza, M.W.; Atherosclerosis 108, 19-25.
36. Interview with Pariza.
37. “Dietary conjugated linoleic acid reduces aortic fatty streak formation greater than linoleic acid in hypercholesterolemic hamsters,” Nicolosi, R.J., and Laitinen, L. (1996), FASEB J. 10 A477.
38. “Ionic Basis of Hypertension, Insulin in Resistance, Vascular Disease and Related Disorders. The Mechanism of ‘Syndrome X”, Resnick, LM, American Journal of Hypertension. 1993 (4Suppl) 123S-134S.
39. “Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting,” Chello-M, et. Al, Ann-Thorac. Surg., 1994, Nov; 58(5): 1427-32.
40. “Immune Modulation by Altered Nutrient Metabolism: Nutritional Control of Immune-Induced Growth Depression,” M.E. Cook, C.C. Miller, Y. Park and Ma Pariza, Poultry Science 72: 1301-1305 (1993).
41. “Feeding Conjugated Linoleic Acid to Animals Partially Overcomes Catabolic Responses Due to Endotoxin Injection,” Miller, C.C., Park, Y., Pariza, M, and Cook, M. Feb. 15, 1994, Biochemical and Biophysical Research Communications, pages 1107-1112.
42. Op. Cit. Cook, Poultry Science, 1993.
43. Interview with Cook.
44. Ibid.
45. Op. Cit. Washington Post.
46. “Obesity, Pathogenesis & Treatment, a series of reports on obesisy issues edited by G. Enzi, et. Al, 1981, Academic Press.
47. William Howard Taft: The President who became Chief Justice, by Severn, Bill 1970, David McKay company.
48. “Conjugated Linoleic Acid Reduces Body Fat,” abstract only of a speech g i ven at En v i ronmental Bi o l o g y, 96. See also U.S. Patent Nu m b e r 5,554,646, dated Sep. 10, 1996.
49. Interveiw with Cook.
50. Information of Dr. Parizi provided to PharmaNutrients, Inc.
51. Interview with Cook.
52. Op. Cit. Parodi.
53. Obesity & Weight Control: The Health Pro f e s s i o n a l’s Guide to Understanding & Treatment. Edited by Frankle, R. T. 1988.
54. Ibid.
55. Op. Cit. The Washington Post.
56. Interview with Pariza.
57. Pariza in information to Pharmnutrients, Inc., indicates a Dr. Reid studied content in 1963 of milk fat.
58. Op Cit. Parodi.
59. Bill Phillips, Supplement Review, 3rd Edition.
60. Interview with Pariza.
61. Interview with Cook.
62. Interviews with Cook, Pariza.
63. Research conducted by Medstat Research Ltd., Lillestrom, Norway for the Herbal Marketing Group, HMG, Ltd., Oslo, Norway. “A pilot study with the aim of stydying the efficacy and tolerability of CLA (Tonalin) on the body composition in humans.) by Erling Thom Ph.D., Medstate Research Ltd., Liilestrom, Norway, July 1997.



--
Vitanet ®

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=401)



VitaNet ® LLC. Discount Vitamin Store.